Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Olema Oncology (Nasdaq: OLMA) announced upcoming poster presentations at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The presentations will showcase new preclinical data on combination therapies for ER+/HER2- breast cancer.
Three posters will be presented on October 24, 2024:
- Combining palazestrant (CERAN) with everolimus (mTOR inhibitor)
- Combining palazestrant with capivasertib (pan-AKT inhibitor)
- Combining OP-3136 (KAT6 inhibitor) with endocrine therapy and CDK4/6 inhibitor
These studies demonstrate enhanced tumor suppression and anti-tumor activity in ER+/HER2- breast cancer models. Abstracts and posters will be available on the ENA website and Olema's website, respectively.
Olema Oncology (Nasdaq: OLMA) ha annunciato le prossime presentazioni di poster al 36° Simposio EORTC-NCI-AACR sui Target Molecolari e le Terapie contro il Cancro (ENA 2024) a Barcellona, Spagna, dal 23 al 25 ottobre 2024. Le presentazioni mostreranno nuovi dati preclinici sulle terapie combinate per il cancro al seno ER+/HER2-.
Tre poster saranno presentati il 24 ottobre 2024:
- Combinazione di palazestrant (CERAN) con everolimus (inibitore di mTOR)
- Combinazione di palazestrant con capivasertib (inibitore pan-AKT)
- Combinazione di OP-3136 (inibitore di KAT6) con terapia endocrina e inibitore di CDK4/6
Questi studi dimostrano un rimaneggiamento migliorato del tumore e un'attività antitumorale nei modelli di cancro al seno ER+/HER2-. I riassunti e i poster saranno disponibili sul sito web di ENA e sul sito web di Olema, rispettivamente.
Olema Oncology (Nasdaq: OLMA) anunció las próximas presentaciones de pósteres en el 36º Simposio EORTC-NCI-AACR sobre Objetivos Moleculares y Terapias contra el Cáncer (ENA 2024) en Barcelona, España, del 23 al 25 de octubre de 2024. Las presentaciones mostrarán nuevos datos preclínicos sobre terapias combinadas para el cáncer de mama ER+/HER2-.
Se presentarán tres pósteres el 24 de octubre de 2024:
- Combinación de palazestrant (CERAN) con everolimus (inhibidor de mTOR)
- Combinación de palazestrant con capivasertib (inhibidor pan-AKT)
- Combinación de OP-3136 (inhibidor de KAT6) con terapia endocrina e inhibidor de CDK4/6
Estos estudios demuestran una supresión tumoral mejorada y actividad antitumoral en modelos de cáncer de mama ER+/HER2-. Los resúmenes y pósteres estarán disponibles en el sitio web de ENA y en el sitio web de Olema, respectivamente.
올레마 온콜로지(Olema Oncology)(Nasdaq: OLMA)는 2024년 10월 23일부터 25일까지 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 분자 표적 및 암 치료 심포지엄(ENA 2024)에서 향후 포스터 발표를 발표했습니다. 발표에서는 새로운 전임상 데이터를 통해 ER+/HER2- 유방암에 대한 조합 요법이 소개될 예정입니다.
2024년 10월 24일에 세 가지 포스터가 발표됩니다:
- 팔라제스트란트(CERAN)와 에버롤리무스(mTOR 억제제)의 조합
- 팔라제스트란트와 카피바세르틴(파나크 AKT 억제제)의 조합
- OP-3136(KAT6 억제제)와 내분비 치료 및 CDK4/6 억제제의 조합
이 연구들은 ER+/HER2- 유방암 모델에서 종양 억제력과 항종양 활성이 향상됨을 보여줍니다. 초록과 포스터는 각각 ENA 웹사이트와 올레마 웹사이트에서 확인할 수 있습니다.
Olema Oncology (Nasdaq: OLMA) a annoncé ses prochaines présentations de posters lors du 36ème Symposium EORTC-NCI-AACR sur les Cibles Moléculaires et les Thérapeutiques contre le Cancer (ENA 2024) qui se tiendra à Barcelone, Espagne, du 23 au 25 octobre 2024. Les présentations mettront en avant de nouvelles données précliniques sur les thérapies combinées pour le cancer du sein ER+/HER2-.
Trois posters seront présentés le 24 octobre 2024 :
- Combinaison de palazestrant (CERAN) avec everolimus (inhibiteur de mTOR)
- Combinaison de palazestrant avec capivasertib (inhibiteur pan-AKT)
- Combinaison de OP-3136 (inhibiteur de KAT6) avec une thérapie endocrinienne et un inhibiteur de CDK4/6
Ces études démontrent une suppression tumorale améliorée et une activité antitumorale dans des modèles de cancer du sein ER+/HER2-. Des résumés et des posters seront disponibles sur le site web de l'ENA et le site web d'Olema, respectivement.
Olema Oncology (Nasdaq: OLMA) gab die bevorstehenden Posterpräsentationen beim 36. EORTC-NCI-AACR-Symposium zu Molekularen Zielen und Krebstherapeutika (ENA 2024) in Barcelona, Spanien, vom 23. bis 25. Oktober 2024 bekannt. Die Präsentationen werden neue präklinische Daten zu Kombinationstherapien für ER+/HER2- Brustkrebs präsentieren.
Drei Poster werden am 24. Oktober 2024 vorgestellt:
- Kombination von Palazestrant (CERAN) mit Everolimus (mTOR-Inhibitor)
- Kombination von Palazestrant mit Capivasertib (pan-AKT-Inhibitor)
- Kombination von OP-3136 (KAT6-Inhibitor) mit endokriner Therapie und CDK4/6-Inhibitor
Diese Studien zeigen eine verbesserte Tumorsuppression und antitumorale Aktivität in Modellen von ER+/HER2- Brustkrebs. Abstracts und Poster werden jeweils auf der ENA-Website und der Olema-Website verfügbar sein.
- New preclinical data showing enhanced tumor suppression in ER+/HER2- breast cancer models
- Multiple combination therapies being explored, potentially expanding treatment options
- Presentations at a major international cancer symposium, increasing visibility for Olema's research
- Data is preclinical, requiring further clinical trials to prove efficacy in humans
- No immediate revenue impact from these research findings
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6 inhibitor, in combination with palazestrant and other targeted agents
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that it will be presenting multiple posters during the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) taking place October 23-25, 2024, in Barcelona, Spain.
Details of the ENA 2024 poster presentations are:
| Title: | Combining palazestrant, a CERAN, and everolimus, an mTOR inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models |
| Poster/Abstract: | 211 |
| Session: | Poster Session 300, Exhibition Hall |
| Date/Time: | Thursday, October 24, 2024, from 09:00 to 17:30 CEST |
| Title: | Combining palazestrant, a CERAN, and capivasertib, a pan-AKT inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models |
| Poster/Abstract: | 212 |
| Session: | Poster Session 300, Exhibition Hall |
| Date/Time: | Thursday, October 24, 2024, from 09:00 to 17:30 CEST |
| Title: | Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2- breast cancer models |
| Poster/Abstract: | 230 |
| Session: | Poster Session 300, Exhibition Hall |
| Date/Time: | Thursday, October 24, 2024, from 09:00 to 17:30 CEST |
Additional information, including abstracts for these presentations, can be found on the ENA website. Copies of the posters will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy.
About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, CNS penetration, and combinability with CDK4/6 inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in Phase 1/2 combination studies with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an mTOR inhibitor (everolimus). For more information on OPERA-01, please visit www.opera01study.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Courtney O’Konek, Vice President, Corporate Communications
media@olema.com
FAQ
What new data is Olema Oncology (OLMA) presenting at ENA 2024?
When and where is Olema Oncology (OLMA) presenting its research at ENA 2024?
What is the significance of Olema Oncology's (OLMA) preclinical combination data?
